Caring For Every Patient And Learning From Every Patient

Caring For Every Patient And Learning From Every Patient

Annual-Meeting

4 months
158 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Yousuf Zafar, MD, discusses the importance of patient care. Financial barriers to clinical trial enrollment are an area of active investigation. Financial toxicity as a concept describes how high costs and financial burden can lead to compromised care and outcomes. Despite the potential to yield large survival benefits and improved access to cutting-edge therapies, less than 5% of adult patients with cancer are enrolled in a clinical trial. Disparities in trial enrollment exist along age, ethnic, and sociodemographic lines, with younger, poorer, nonwhite patients with private insurancethe exact population who may be at highest risk for financial toxicityless likely to participate. Cost and insurance concerns remain an obstacle for clinical trial enrollment for certain patient populations. Changing the clinical trial paradigm with a focus on addressing structural and clinical barriers to clinical trial enrollment is paramount. This includes expanding access to clinical trials within community populations, advocating for health policy changes to guarantee insurance coverage of clinical trial standard-of-care health care, and considering noncoercive financial assistance (particularly for indirect costs like travel and lodging) for participants to defray their additional costs of participation. Additional steps toward education, cost transparency, and expansion of foundation assistance may also improve equitable access to clinical trials for all.
Up Next Autoplay
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Category: Gastrointestinal Cancer
172 Views
obr 3 months
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
Category: Gastrointestinal Cancer
216 Views
Annual-Meeting 4 months
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Category: Gastrointestinal Cancer
26 Views
Annual-Meeting 4 months
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Category: Gastrointestinal Cancer
126 Views
Annual-Meeting 4 months
The Quality and Completeness of Data
The Quality and Completeness of Data
Category: Gastrointestinal Cancer
113 Views
Annual-Meeting 4 months
Financial Toxicity and Equitable Access to Clinical Trials
Financial Toxicity and Equitable Access to Clinical Trials
Category: Gastrointestinal Cancer
64 Views
Annual-Meeting 4 months
Safety Profile for Pembrolizumab
Safety Profile for Pembrolizumab
Category: Gastrointestinal Cancer
20 Views
Annual-Meeting 4 months
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Category: Gastrointestinal Cancer
77 Views
Annual-Meeting 4 months
Combining Chemo & Immunotherapy Did Not Help Patients: Hope To See Survival Level Off As Data Matures
Combining Chemo & Immunotherapy Did Not Help Patients: Hope To See Survival Level Off As Data Matures
Category: Gastrointestinal Cancer
35 Views
Annual-Meeting 4 months